Genprex, Inc. — Investor Relations & Filings
Filings indexed
465
across all filing types
Latest filing
2026-04-30
Regulatory Filings
Country
US
United States of America
Listing
US
GNPX
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapeutic options for large patient populations. Its oncology pipeline includes clinical-stage programs for lung cancer, such as the Acclaim-3 trial in small cell lung cancer (SCLC) and other programs for non-small cell lung cancer (NSCLC). In addition to its cancer programs, Genprex is developing gene therapies for diabetes. The company utilizes a proprietary, non-viral nanoparticle delivery system to systemically deliver therapeutic genes.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-04-30 | English | |
| 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-04-28 | English | |
| 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-04-21 | English | |
| 4 - GENPREX, INC. (0001595248) (Filer) | 2026-02-27 | English | |
| 4 - GENPREX, INC. (0001595248) (Filer) | 2026-02-27 | English | |
| 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-02-23 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
12 filings
| |||||
| 39079012 | 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-04-30 | English | ||
| 37966942 | 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-04-28 | English | ||
| 34744649 | 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-04-21 | English | ||
| 32894757 | 4 - GENPREX, INC. (0001595248) (Filer) | 2026-02-27 | English | ||
| 32894758 | 4 - GENPREX, INC. (0001595248) (Filer) | 2026-02-27 | English | ||
| 32827314 | 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-02-23 | English | ||
| 30796874 | SCHEDULE 13G Filing | 2026-02-11 | English | ||
| 19423450 | 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-02-10 | English | ||
| 12735587 | FORM 8-K | 2026-01-09 | English | ||
| 12735588 | FORM S-8 | 2026-01-09 | English | ||
| 12735590 | FORM 8-K | 2026-01-07 | English | ||
| 12735589 | FORM 8-K | 2026-01-06 | English | ||
|
2025
3 filings
| |||||
| 12735591 | FORM 4 | 2025-12-23 | English | ||
| 12735592 | FORM 4 | 2025-12-23 | English | ||
| 12735593 | FORM 4 | 2025-12-23 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Genxone Spolka Akcyjna
A biotechnology company specializing in Next Generation Seq…
|
GX1 | PL | Professional, scientific and te… |
|
GeoVax Labs, Inc.
Clinical-stage biotech developing vaccines and therapies fo…
|
GOVX | US | Professional, scientific and te… |
|
GH Research PLC
Develops mebufotenin-based therapies for psychiatric and ne…
|
GHRS | IE | Professional, scientific and te… |
|
GI Innovation Inc.
Researches and develops protein-based drugs for immuno-onco…
|
358570 | KR | Professional, scientific and te… |
|
Ginkgo Bioworks Holdings, Inc.
Operates a horizontal platform for cell programming and syn…
|
DNA | US | Professional, scientific and te… |
|
GRAIL, Inc.
A healthcare company developing blood tests for multi-cance…
|
GRAL | US | Professional, scientific and te… |
|
GT Biopharma, Inc.
Clinical-stage immuno-oncology company developing therapies…
|
GTBP | US | Professional, scientific and te… |
|
Guard Therapeutics International AB
Clinical-stage biotech developing therapies to prevent acut…
|
GUARD | SE | Professional, scientific and te… |
|
Gubra A/S
Biotech and CRO focused on peptide drugs for metabolic and …
|
GUBRA | DK | Professional, scientific and te… |
|
HALOZYME THERAPEUTICS, INC.
Biopharmaceutical firm licensing technology to convert IV d…
|
HALO | US | Professional, scientific and te… |
Genprex, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35333/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35333 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35333 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35333 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35333}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Genprex, Inc. (id: 35333)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.